Galapagos (NASDAQ:GLPG) and XOMA Royalty (NASDAQ:XOMA) Head-To-Head Contrast

XOMA Royalty (NASDAQ:XOMA) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Profitability

This table compares XOMA Royalty and Galapagos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	45.75%	10.32%	3.49%
Galapagos	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings for XOMA Royalty and Galapagos, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	1	2	3	0	2.33
Galapagos	1	5	0	1	2.14

XOMA Royalty currently has a consensus price target of $61.60, suggesting a potential upside of 86.78%. Galapagos has a consensus price target of $36.50, suggesting a potential upside of 24.07%. Given XOMA Royalty’s stronger consensus rating and higher probable upside, equities research analysts clearly believe XOMA Royalty is more favorable than Galapagos.

Insider & Institutional Ownership

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 32.5% of Galapagos shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Comparatively, 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares XOMA Royalty and Galapagos”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15 million	7.54	$31.71 million	$1.46	22.59
Galapagos	$1.26 billion	1.54	$363.05 million	($1.57)	-18.74

Galapagos has higher revenue and earnings than XOMA Royalty. Galapagos is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

XOMA Royalty has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

Summary

XOMA Royalty beats Galapagos on 12 of the 15 factors compared between the two stocks.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.